Royalty Report: Wound Care, Drugs, Medical – Collection: 299291

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Wound Care
  • Drugs
  • Medical
  • Therapeutic
  • Pharmaceuticals
  • Supply
  • Surgical
  • Antimicrobial
  • Skin care
  • Pain

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 299291

License Grant
Licensor grants Licensee of the Cayman Islands an exclusive license under the Licensed Patents and Licensed Technology in both cases to make, have made, use, sell, offer to sell, import, and otherwise distribute and dispose of Products in each case solely in the Field throughout the Territory.

Licensor grants a non-exclusive license to use the Licensor Marks solely in connection with the marketing, promotion and sale of the Product(s) in the Field.

License Property
Licensor is the sole owner of Patent entitled Use of physiologically balanced, ionized, acidic solution in wound healing.

Product shall mean any product comprising any formulation containing hypochlorous acid as its principal active ingredient including that product known as NVC-101.

NVC-101 is a topical antimicrobial that can decrease the bacterial bioburden of chronic wounds.

Field of Use
The Field shall mean, with respect to Products, all commercial uses of the Products for wound care, wound healing, wound cleaning, wound debridement, wound disinfection, wound inflammation, wound exudate management, wound granulation, wound reepithelialization and any other form of wound treatment or wound management including use in surgical wounds and associated disinfection as well as any other treatments that may be adapted to be assisted by reduced pressure, all in humans, but shall exclude for all purposes any products or uses intended for the eye, ear or nose, including the prevention or treatment of any infection thereof.

IPSCIO Record ID: 614

License Grant
The Licensors grants the Licensee a non-revocable, exclusive, sub-licensable, transferable right in and to the Licensed IP to make, have made, use, sell, export, reproduce, market and distribute Products for External Wound Care in the field of use.
License Property
External Wound Care means the treatment of external, tunneled or undermined wounds (including, without limitation, pressure ulcers (Stages I – IV), venous stasis ulcers, diabetic ulcers, ulcers resulting from arterial insufficiency, surgical wounds, traumatic wounds, first and second degree burns, superficial wounds, cuts scrapes, skin tears, skin flaps and skin grafts.

Patent means – United States Patent No. 6,136,341.

The patented technologies and processes related to CellerateRxTM, an advanced collagen based wound care product formulation.  These new licenses are limited to the human health care market for external wound care, and include any new product developments based on the licensed patent and processes.

Field of Use
The Field of Use means the worldwide human health care market, (excluding the veterinary, nutritional and injectable markets as well as all other uses) and subject to certain exceptions.

IPSCIO Record ID: 180166

License Grant
The Israeli Licensor grants to the Israeli Licensee an exclusive, perpetual, worldwide license under the Licensed Information to research, develop, make, have made, manufacture, use, sell, offer for sale, sublicense, import, export, commercialize and distribute, and grant sublicenses with respect to any and/or all of the foregoing, Licensed Products.

Licensee shall be entitled to grant Sublicenses to third parties at Licensee’s discretion, provided Licensor’s rights are not adversely affected by such Sublicenses, and provided that Licensee shall guarantee performance of all financial liabilities hereunder by any Sublicensee.

License Property
Licensor represents that it owns all rights in and to the patent application known as PCT/IL2009/000946, which Patent relates to a wound dressing and methods of preparation and use thereof for promoting healing of wound bed.  The wound dressing is advantageous for application to a debrided wound bed. The wound dressing comprises an open conduit polymeric foam matrix, and a hydrophilic polymer which is disposed in dry form on the inner surfaces of the conduits within the matrix.

The present invention provides a wound dressing for application onto a wound bed following debridement, and methods of use thereof to create an interface layer microenvironment (ILM) conducive to wound healing.

Field of Use
This agreement related to the medical industry.

IPSCIO Record ID: 304408

License Grant
The Company has an exclusive sublicense to distribute CellerateRX® Activated Collagen® products into the wound care and surgical markets in the United States, Canada and Mexico.
License Property
CellerateRX® is a wound and skin care product for use by surgeons on surgical wounds consisting of a Surgical Powder that is a medical hydrolysate of Type I bovine collagen.  When applied to a surgical wound, the hydrolyzed collagen is ready to aid in the natural wound healing process.

Licensor manufactures the products and owns the CellerateRX registered trademark.

Field of Use
CellerateRX Surgical Powder is a medical hydrolysate of Type I bovine collagen indicated for the management of
Surgical wounds
Traumatic wounds
Partial- and full-thickness wounds
First- and second-degree burns

Licensee will utilize the wound and skin care products for external wounds, including the treatment of external, tunneled or undermined wounds.  These products are used by surgeons in the medical industry. This would include pressure ulcers (Stages I-IV), venous stasis ulcers, diabetic ulcers, ulcers resulting from arterial insufficiency, surgical wounds, traumatic wounds, first and second-degree burns, superficial wounds, cuts, scrapes, skin tears, skin flaps and skin grafts.

The Licensees business is developing, marketing, and distributing wound and skin care products to physicians, hospitals, clinics and post-acute care settings.

IPSCIO Record ID: 309459

License Grant
By the initial agreement Licensor grants to Licensee, its subsidiary, certain rights to Licensor’s technologies in the field of human Wound Care.  The original license was exclusive.

The parties now hereby agree to amend, modify and supplement the License Agreement as follows in order to include additional products developed by Licensee
–  the definition of Field of Use in the License Agreement,
–  the definition of Wound Care in the License Agreement.

License Property
Licensee has developed a product called Clyraguard, a derivative of the licensed technologies, that it believes could fulfill a pivotal role in the COVID-19 pandemic, and desires to manufacture, market and sell that product.

Additionally, the License Agreement contemplates thirteen expanded Fields of Use,  which include oral/dental/periodontics mouthwash and rinse, hydration for patients, and Licensee has developed such a product (OraClyr), and therefore desires to further expand the License to include such product.

As of this amendment, Wound Care means articles, compositions, and methods for medical treatment to treat a condition comprising damage to a human patient, the condition including substantive traumatic or non-traumatic breach of the derma. Such medical treatment may include extended application of an article of manufacture (wraps, bandages, bandaids and appliqués) over the epidermis, or wipes or direct application of medication such as liquid, ointment, spray, cream or paste, including any chemistry used on or in a patient during surgery. As non-limiting examples of traumatic damage are cuts, scrapes, punctures, incisions and other intentional or accidental penetration damage through the epidermis. As non-limiting examples of non-traumatic damage are treatment, prophylaxis or prevention of sores, topical infections, insect bites, sub-epidermal infections, boils, and lesions (in the absence of a previous wound at the site). Wound Care includes surgical damage to tissues and organs during surgical or other medical procedures as well as from accidental damage to tissues and organs. Surgical and medical procedures, and traumatic events, also include care of the mouth, gums, eyes, optical system and all other organs and tissues. Wound Care does NOT include products intended for the treatment of animals.

As of this amendment, Licensed Processes means any method, process, modality, procedure, practice, or course of action within the Field of Use covered by a claim of Patent Rights, and/or that incorporates or includes know-how, trade secret, or proprietary information of Licensor.

As of this amendment, Licensed Products means any means any article, kit, equipment, system, method, apparatus or unit within the Field of Use covered by a claim of Patent Rights and/or that incorporates or includes know-how, trade secret, or proprietary information of Licensor.

Licensors business objective is to harness and deliver nature’s best disinfectant – iodine – in a safe, efficient, environmentally sensitive and cost-effective manner. The core of this innovative technology is the accurate and safe delivery of iodine in a wide range of forms, moieties and conditions.

Field of Use
Clyraguard is a personal protective spray designed to help prevent cross contamination of the personal protective equipment worn by front-line healthcare workers by the SARS-CoV-2 coronavirus, the cause of COVID-19 disease.

The Licensee has received test results showing that its proprietary copper iodine antimicrobial and antiviral product, Clyraguardâ„¢, successfully inactivated the COVID-19 coronavirus (SARS-CoV-2 virus), the virus responsible for the current worldwide pandemic.

Licensee was formed by Licensor to commercialize our technology in the medical products industry, with an initial focus on advanced wound care.

As of this agreement, Field of Use means prescription-based and over-the-counter products in
(i) the commercial field of human Wound Care in the medical, dental and ophthalmologic fields of prescription-based; and
(ii)  the commercial field of oral, dental, and periodontis, including mouthwash and rinse, and hydration for patients.

(iii)  Field of Use does NOT include products or processes intended for use on surfaces (e.g., disinfection of a hospital floor or other a hard surface) or other devices usable in a medical setting (e.g., disinfection of a metal instrument used to treat a patient). Field of Use does NOT include over-the-counter products available without a prescription.

IPSCIO Record ID: 3465

License Grant
The Licensor receives royalties on the Licensee's sales.
License Property
The Licensor is a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, which significantly reduces the need for antibiotics while reducing infections and accelerating healing.

Microcyn Technology is a unique shelf-stable pH-neutral oxychlorine compound. Microcyn has been studied for its clinical benefits and safety, a number of these findings peer-reviewed and published. These studies demonstrate that the Microcyn Technology delivers wound healing benefits, reduction of inflammation, cure or improvement of infection and antimicrobial activity; all while remaining safe and biocompatible as evidenced in a 2007 study published in the International Wound Journal. The reason for this safety is that mammalian cells have evolved with special pumps to regulate the active ingredients in Microcyn Technology while viruses, spores and bacteria, including drug-resistant bacteria, lack this ability.  The technology behind the Microcyn® Technology-based family of products involves a unique, patented electrochemical treatment of dilute saltwater. A pH neutral solution of hypochlorous acid, and its sodium salt, hypochlorite, is generated. Hypochlorous acid is a natural product the human body produces in response to injury.

Several solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores; increase blood flow to the wound site; and reduce both inflammation and pain while assisting in faster wound closure.

Field of Use
The Microcyn Technology addresses the need for improved solutions in multiple markets including dermatology, oral care, cosmeceutical, wound care and others.

IPSCIO Record ID: 275061

License Grant
Licensee acquired an exclusive world-wide license to market, sell and further develop antimicrobial products  utilizing certain Licensor patents and pending patent applications.  A director and indirect principal shareholder of Licensee is also a director of Licensor, and indirectly a significant shareholder of Licensor, and through the potential exercise of warrants a majority shareholder.
License Property
Currently, the products covered by the License Agreement are BIAKOSâ„¢ Antimicrobial Wound Gel, and FDA cleared BIAKOSâ„¢ Antimicrobial Skin and Wound Cleanser.
Field of Use
The field of use is for the prevention and treatment of microbes on the human body.  The agreement pertains to the wound care industry.

IPSCIO Record ID: 3286

License Grant
The Licensor entered into a License Agreement granting our subsidiary, the Licensee, the exclusive world-wide right to make, have made, use, sell, offer for sale, and import products for use within the field of human wound care, expandable to include other medical products. The Licensee has the rights to sub-License the technology.
License Property
The Licensee will commercialize the Licensor technology in the medical products industry, with an initial focus on advanced wound care. The advanced wound care products combine broad-spectrum antimicrobial capabilities with iodines natural and well-understood metabolic pathway to promote healing.

IPSCIO Record ID: 26656

License Grant
A U.S. pharma has granted the worldwide rights to a U.S business unit of an Italian company the Knighton patent for all applications relating to the use of autologous platelet releasate therapies for healing purposes (wound-healing and tissue repair therapies).  U.S. Patent No. 5,165,938 entitled Wound Healing Agents.
License Property
5,165,938 A process for treating a wound of a live animal which comprises applying over the wound an effective amount of a treating composition containing the materials released by platelets during the platelet release reaction and facilitating healing of the wound.
Field of Use
Licensed Fields means any and all fields of use.

IPSCIO Record ID: 227278

License Grant
University hereby grants to Licensee in the territory and in the field an exclusive commercial license under University patent rights, to make and have made, to use and have used, to sell and have sold the licensed products, and to practice the licensed processes, for the life of the university patent rights. Such licenses shall include the right to grant sublicenses.
License Property
Universitys rights in the United States Patents listed below, and the inventions described and claimed therein
U.S.P.N. 5,019,559 – Wound healing using PDGF and IGF-II
U.S.P.N. 4,861,757 – Wound healing and bone regeneration using PDGF and IGF-I
U .S.P.N. 5,124,316 – Method for periodontal regeneration
U.S.P.N. 4,874,746 – Wound healing composition of TGF-alpha and PDGF
U .S.P .N. 4,983,581 – Wound healing composition of IGF-I and TGF-.beta.
U.S.P.N. 5,256,644 – Wound healing using IGF-II and TGF
U.S.P,N. 5,034,375 – Process of wound healing using PDGF and EGF
U.S.P.N. 5,035,887 – Wound healing composition of IL-1 and PDGF or IGF-1
U.S.P.N. 5,516,699 – Pyridinoline crosslinks as markers of periodontal and peri-implant disease activity

rhPDGF is a bio-active protein that is a key mediator of wound healing and tissue regeneration.

Field of Use
rhPDGF is a key stimulator of the body's natural wound healing process. It has a well-established mechanism of action that leads to stimulation of certain cell types, including those important to bone, cartilage, tendon and ligament healing.

IPSCIO Record ID: 369299

License Grant
Licensor hereby grants to Licensee a license under the Licensed Technology to use and sell the Licensed Products in the Field in the Territory. The license granted does not include any rights of Licensee to grant sublicenses to any Third Party or to have Licensed Products sold by any Third Party on behalf of Licensee, except that Licensee may utilize Sales Representatives.
License Property
U.S. Patent 7,276,255 – Wound and ulcer treatment with super-oxidized water

Licensed Products shall mean only those Licensor proprietary Vashe solution products that are described in Agreement.
Product irrigating solution with the following characteristics.
– packaged in bottles or bags;
– that can be hung on an IV pole and are 'spikeable' via a septum;
– only the 125 ml, 250 ml and 500 ml size pre-filled containers; and
– have a shelf life of 12 months.
– Licensee shall also have the right to sell the foregoing Vashe products that also has
the following characteristics, but only if and as available
– is 'sterile'; and
– have a shelf life greater than 12 months

Field of Use
Vashe® wound therapy product is a solution intended for cleansing, irrigating, moistening, and debriding acute and chronic dermal lesions.  Use of the new product will be emphasized in conjunction with clinical procedures performed with Licensee's ultrasonic systems and gives surgeons and clinicians an expanding line of products for treating wounds.

Field, prior to the market availability of sterile Licensed Product, shall mean the use of the Licensed Product as an irrigating solution specifically for the treatment of human wound care with emphasis on use in conjunction with therapeutic ultrasonic procedures. After market release of sterile Licensed Product.

Field shall mean the use of the Licensed Product, both sterile and non-sterile, as an irrigating solution specifically for the treatment of human wound care principally in conjunction with therapeutic ultrasonic procedures.

IPSCIO Record ID: 282564

License Grant
Licensee executed a license agreement with Licensee (director of Licensee is also a director and significant shareholder of Licensor), whereby Licensee acquired an exclusive world-wide license to market, sell and further develop antimicrobial products for the prevention and treatment of microbes on the human body.

Licensee acquired an exclusive world-wide license to market, sell, distribute, and further develop certain antimicrobial barrier film and skin protectant products, utilizing certain Licensor patents and pending patent applications.

License Property
The products covered by the License Agreement are BIAKOSâ„¢ Antimicrobial Barrier Film and a skin protectant product with a registered trademark pending.

BIAKS is an FDA-cleared and patented composition that effectively disrupts extracellular polymeric substances to eradicate biofilm microbes. BIAKS is intended for mechanical removal of debris, dirt, foreign materials, and microorganisms from wounds including stage I-IV pressure ulcers, diabetic foot ulcers, post-surgical wounds, first and second-degree burns as well as grafted and donor sites. BIAKS is effective in killing free-floating microbes, immature, and mature bacterial biofilms such as MRSA and Pseudomonas aeruginosa, and fungal biofilms such as Candida albicans. In addition, BIAKS safety studies show that it is non-cytotoxic, non-irritating, and non-sensitizing to healthy skin and assists in the normal wound healing process.

8,852,648 Delivery of biologically-active agents using volatile, hydrophobic solvents

8,877,882 Non-self-adherent coating materials

Field of Use
The currently licensed products are BIAKOSâ„¢ Antimicrobial Wound Gel, and FDA cleared BIAKOSâ„¢ Antimicrobial Skin and Wound Cleanser.

BIAKOSâ„¢ Antimicrobial Skin & Wound Cleanser is a patented product that effectively disrupts extracellular polymeric substances to eradicate biofilm microbes. BIAKOS Antimicrobial Skin & Wound Cleanser also provides mechanical removal of debris, dirt, foreign materials, and microorganisms from wounds including stage I-IV pressure ulcers, diabetic foot ulcers, post-surgical wounds, first and second-degree burns as well as grafted and donor sites. BIAKOS Antimicrobial Skin & Wound Cleanser is effective in killing free-floating microbes, immature, and mature bacterial biofilms such as MRSA and Pseudomonas aeruginosa, and fungal biofilms such as Candida albicans. In addition, BIAKOS Antimicrobial Skin & Wound Cleanser safety studies show that it is non-cytotoxic, non-irritating, and non-sensitizing to healthy skin and assists in the normal wound healing process.

IPSCIO Record ID: 3180

License Grant
In this agreement, the Licensor established a joint venture company with a German Company, the entity is the Licensee.

The Licensor has granted the Licensee global distribution rights in this regard.

This new enterprise is charged with obtaining the CE mark certification authorizing the distribution of the Hemospray wound spray in the member states of the European Union.

License Property
Hemospray Wound Spray

The Licensor has developed a novel medical product aimed at the healing of chronic wounds. Chronic wounds are a medical problem of increasing importance as they originate from widespread risk factors such as diabetes, obesity, smoking etc. Lack of oxygen supply to the cells in the wound ground is the main reason why those wounds lose their genuine healing power. Based on its concept of artificial oxygen carriers, our Hemospray wound spray product bridges the watery wound surface and permits an enhanced afflux of oxygen to the wound ground.

IPSCIO Record ID: 1396

License Grant
The Licensee entered into separate exclusive license agreements with both Licensor and its founder.

Licensee obtained the exclusive worldwide license to certain patented technologies and processes related to CellerateRX. Licensee had been marketing and selling CellerateRX during the previous four years under the terms of a distribution agreement with Licensor that was terminated in 2005.  The new licenses are limited to the human health care market for external wound care including surgical wounds, and include any new product developments based on the licensed patent and processes and any continuations.

License Property
CellerateRX is a patented collagen wound care product.

CellerateRX has a competitive proprietary feature and performance advantages over other collagen-based products. It is available in powder (95% collagen) and gel (65%) forms that don't need special handling (like refrigeration). It is active in all 4 phases of wound healing.

Field of Use
The new licenses are limited to the human health care market for external wound care including surgical wounds, and include any new product developments based on the licensed patent and processes and any continuations.

IPSCIO Record ID: 279344

License Grant
Licensor grants an exclusive option, for the duration of the Option Period, to acquire an exclusive right and license, with a right to grant and authorize sublicenses under the Patent Rights and Related Technology, to make, use and sell Licensed Products, to practice any process, method or procedure of the Patent Rights and Related Technology and to otherwise exploit the Patent Rights and the Related Technology.
License Property
The patents are for Compositions containing protease produced by vibrio and method of use in debridement and wound healing .
Field of Use
Licensee is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions.

IPSCIO Record ID: 4355

License Grant
The Licensor hereby grants to the Licensee, an exclusive, worldwide royalty-bearing, assignable, transferable, irrevocable License with the right to grant sublicenses of the Licensee Products, and to make or to have made for the Licensee’s use, import, or offer for sale, or any combination thereof, Licensee Products within the territory.
License Property
Licensed Technology means any intellectual property, invention, know-how, trade secrets, technical information, research and development information, test results, and data that comprise or form part of the certain invention concerning SilverlonOTC Wound Care

Licensed Patents
U.S. 7,230,153 C2
U.S. 7,291,762 B2
U.S. 7,989,674 B2
U.S. 8,093,444 B2
U.S. 8,118,791

Field of Use
The licensing agreement enables the Licensee to develop, market and sell OTC wound care products based on Silverlon’s proprietary silver coating technology, which provides superior performance for wound treatment. The technology, with its permanently plated metallic surface, reduces the occurrence of surgical site infections.

IPSCIO Record ID: 783

License Grant
This Amendment No. 1 is made in full settlement of any rights either party may have to OBIs products Woundecyte â„¢, Dermacyte â„¢, and any other cosmetic or dermatology products which OBI has or will develop which will employ a perfluorocarbon (PFC) gel.  The Licensor shall be deemed to have been a contributor on the development of perfluorocarbon (PFC) gel based products used to treat burns and wounds, whether with our without the use of a bandage or with or without the use of an oxygen generator. This includes Woundecyte â„¢. For purposes of the License Agreement, the PFC gel based products used to treat burns and wounds will be considered Licensed Products, whether or not any patents are obtained on the PFC gel based products used to treat burns and wounds, and OBI will be obligated to pay milestone, sublicensing and royalty payments on the PFC gel based products used to treat burns and wounds.
License Property
1. PCT application, filed May 14, 2007, Publication No. WO2007134304 entitled “Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides” based on VCU invention 06-31

2. Provisional patent application, filed 02/13/2008, Serial No. 61/028230, entitled “Gas Based Wound and Tissue Therapeutics”, based on VCU invention VCU 08-008

3. Provisional patent application, filed 12/10/2007, Serial No. 61/012,508, entitled “Novel Combinatorial Approaches to Enhance Oxygen Transport to Tissues”, based on VCU invention VCU 07-080

Traditional treatment of wounds, such as burns, chronic skin ulcers and the like has relied on ensuring proper intravascular resuscitation to help ensure adequate perfusion of the wounds to maintain levels of oxygen in the wound capable of meeting tissue needs and thus promote survival and healing. When perfusion is severely jeopardized, for example in cases of chronic wounds such as pressure, diabetic, venous stasis and arterial ulcers where the vasculature has been severely damaged over time, the use of hyperbaric oxygen has been advocated as a means to enhance oxygenation. In addition to being bactericidal and static, intermittent use of hyper- oxygenation is believed to be beneficial as it may lead to increased tissue oxygenation and ultimate angiogenesis . Furthermore, increased tissue oxygenation may assist in decreasing the inflammatory response.

IPSCIO Record ID: 264136

License Grant
The Licensor, an individual, hereby grants to Israelis Licensee with effect from the Effective Date subject to the terms of this Agreement, an exclusive license under and using the Intellectual Property and Improvements for the purpose of developing, using, marketing, supplying and selling the Product in the Territory, with the right to sub-license.
License Property
Licensor is the owner of certain patents and proprietary information and know-how relating to a pharmaceutical product known as debridase, based on Bromelain which product may be used for debriding bums and other wounds.

“Bromelain” means the raw material derived from pineapple sterns and specially processed for the Product.

NexoBrid has been designated an orphan drug and for the treatment of severe burns.  NexoBrid’s label provides that it only be used in specialized burns centers or by burn specialists

NexoBrid is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. The removal of eschar is a procedure also known as debridement. Debridement is a critical first step in the successful healing of severe burns and chronic and other hard-to-heal wounds. Under existing SOC, burn eschar may be removed either by employing certain existing topical agents that have been found to be minimally effective or that take a significantly longer period of time to work, or by resorting to non-selective surgery, which is traumatic and may result in loss of blood and viable tissue. NexoBrid’s rapid and selective debridement alleviates the known risks associated with eschar, such as infection, eventual sepsis, wound deterioration and consequential scarring, and it allows physicians to reach an informed decision on further treatment at an earlier stage by direct visual assessment of the actual burn depth. Furthermore, NexoBrid minimizes the burden associated with invasive surgical procedures, reduces the need for skin grafting and sacrifice of healthy tissue from donor sites on a patient’s body and generally results in a more favorable overall long-term patient outcome. NexoBrid has been investigated in hundreds of patients across more than 15 countries and four continents in seven completed Phase 2 and Phase 3 clinical studies

The claims of such patents are directed to a process of preparing a mixture of escharase and proteolytic enzymes and cover the underlying proteolytic mixture of escharase and proteolytic enzymes prepared by that specific process.

US Patent No 5, 830,739

Field of Use
Field” means the treatment of all forms of burns and other wounds in humans by way of debriding with debridase or other products derived using the Technology.

This agreement pertains to the drug industry relating in the fields of severe burns as well as chronic and other hard-to-heal wounds and connective tissue disorders.

IPSCIO Record ID: 256319

License Grant
The University grants a worldwide right and license to make, have made, use, lease, sell, and sublicense the Pre-issuance Products and Licensed Products under the Patent Rights, and to practice and sublicense the Pre-issuance Processes and Licensed Processes to the full end of the term(s) for which Patent Rights are granted unless sooner terminated as hereinafter provided.
License Property
The Invention will mean a wound treatment technology, Method and Apparatus to Enhance Closure and Health of Open Wounds.

The patents are Wound Dressing and Treatment Method, Fluidic Connection System and Method, and, Fastening System and Method.

Field of Use
Licensee is a global medical technology company in advanced wound care and therapeutic surfaces.

IPSCIO Record ID: 203522

License Grant
For the License to Finished Products,  Licensor grants the Licensee of Portugal, only in the Territory, the sole and exclusive, transferable, sub-licensable right in the Field of Use under the Know-How, the Documentation, the Licensor Improvements, Joint Improvements and the Patents
– to use Bulk Active Material to produce or have produced Finished Products only for making Sales in the Field of Use, either directly, through its Affiliates or through Distributors or Sub-Licensees, in the Territory; – and, to use Bulk Active Material to conduct internal research and development activities relative to and for the benefit of making Joint Improvements or Licensee Improvements to Finished Products.

For the License to Trademark for the Bulk Active Material, Licensor grants, only in the Territory, to Licensee a non-exclusive, transferable, sub-licensable right in the Field of Use to use, copy, publish, display, distribute and disseminate, on or in any tangible form or electronic media, the Trademark for the Bulk Active Material only in connection with the Sale of Finished Products in the Field of Use and associated marketing collaterals and packaging in accordance with the Trademark Style Guide and Requirements.

License Property
Thymosin beta 4 (TB4) is a novel drug undergoing human clinical trials for chronic wounds.

TB4 is a naturally occurring 43-amino acid peptide present in virtually all human cells. TB4 represents a new class of wound healing drug and is different from other wound repair factors, such as growth factors, in that it promotes endothelial cell differentiation and keratinocyte cell migration, down-regulates a number of inflammatory cytokines and chemokines, and has a very low molecular weight, allowing it to diffuse relatively long distances through tissues. A key mechanism of action is TB4's ability to regulate the cell-building protein, actin, a vital component of the cytoskeleton. It has been the subject of a significant amount of research at the NIH and a number of other academic institutions, and has been reported to be effective in the repair of dermal and corneal wounds in numerous animal models under a variety of conditions.

Patents are for Methods of treating Epidennolysis Bullosa and Other similar Dermatological Indications with Thymosin Beta 4, Analogues, isoforms and Other Derivatives, Treatment of Infections and Other Disorders, Thymosin B4 Promotes Wound Repair,  Methods of Treating and Preventing Anthrax Induced Pathologies with Thymosin Beta 4 Analogs, isoforms and Other Derivatives incorporated into 2600-108, Methods of Healing or Preventing Inflammation, Damage and Other Changes that Occur prior to, During or Immediately after a Myocardial Event with Thymosin Beta 4, Analogues, isoforms, and other Derivatives, Methods of Healing, Treating and/ or Reversal of Stenosis or ·Restenosis of the Myocardium and Coronary Vessels, Heart Valves and Septa Injuries or Defects Using Thymosin Beta 4, or TB4 Analogues, isoforms, Antibodies or anti-sense Peptides, and, Methods of Treating and Preventing Physical, Cognitive and Biological Damage Due to Ionizing Radiation Exposure by Administering LKKTET Peptides, TB4, analogues, isoforms and Other Derivatives.

Finished Product means any prescription or over-the-counter pharmaceutical product, or a medical device, in the Field of Use containing the Bulk Active Material.

The trademark will be determined by Licensee and approved by Licensor.

Field of Use
The field of use means the availability and use of the Finished Products formulated for the prevention and/or treatment of any indication for external wounds and internal wounds. For the sake of clarity, such indications shall include, but not be limited to, the gastrointestinal tract and burns; and shall not include ocular wounds. It is understood that any treatment or use of the Finished Products may not be incorporated into the form of any type of cosmetic product.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.